Brett Theeler

National Institutes of Health

Disclosure: Nothing to disclose

Presentation(s):

• HOUT-22 - Evaluating clinical impact utilizing the RANO-PRO Collaborative’s standardized priority constructs

  Friday, November 22
  2:15 PM – 2:20 PM

• RARE-10 - Improving care for adult patients with rare CNS tumors:  The National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) program and clinic

  Friday, November 22
  7:30 PM – 9:30 PM

• HOUT-04 - Association of common patient-reported immunotherapy symptomatic side effects and pseudoprogression in patients with primary central nervous system (CNS) tumors

  Friday, November 22
  7:30 PM – 9:30 PM

• NIMG-32 - Challenges of imaging interpretation to predict Oligodendroglioma grade

  Friday, November 22
  7:30 PM – 9:30 PM

• QOLP-36 - The importance of sleep disturbance in primary brain tumor (PBT) patients: Clinical characteristics & co-occurrence with tumor-related & psychological symptoms

  Friday, November 22
  8:06 PM – 8:10 PM

• RARE-35 - MRI Findings at Progression in Adult Patients with Medulloblastoma

  Saturday, November 23
  5:00 PM – 7:00 PM

• ACTR-62 - Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent high-grade astrocytoma in adults

  Saturday, November 23
  5:16 PM – 5:20 PM